In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
GBR 1302 is Glenmark's leading investigational immuno-oncology agent and is based on Glenmark's proprietary BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) platform